In 2025, the Germany registered a value of USD 27.62 billion.
Our market findings show the Germany Infusion Services Market is expected to surpass USD 49.88 billion by 2033, with a projected CAGR of 7.7% during the forecast timeframe.
Germany’s hospital-centric reimbursement model preserves strong facility-based infusion dominance, supported by statutory health insurance coverage for biologic therapies.
The Federal Statistical Office reports sustained oncology treatment volumes, supporting stable infusion utilization across public and private hospitals.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]